[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-serous-chorioretinopathy-csc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-serous-chorioretinopathy-csc":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645380","phase-2-faricimab-for-chronic-central-serous-chorioretinopathy-a-randomized-sham-controlled-trial-100645380",false,"NCT07681167","Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial","A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial","Inclusion Criteria:\n\n* Age ≥21 years at the time of consent.\n* Best corrected visual acuity between 24 and 73 ETDRS letters (approximately Snellen equivalent 20\u002F32 to 20\u002F300) in the study eye.\n* Diagnosis of chronic CSCR, defined as the presence of persistent SRF for ≥3 months, with or without secondary MNV.\n* Presence of pachychoroid features, including pachyvessels on ultra-widefield imaging in at least one quadrant and SFCT ≥300 µm.\n* Presence of intraretinal fluid and\u002For subretinal fluid involving the fovea, as confirmed by OCT.\n* Disease duration criteria:\n\n  * CSCR without secondary MNV: persistent subretinal fluid for ≥3 months despite observation, or\n  * CSCR with secondary MNV: presence of exudative fluid of any duration, with neovascularization confirmed on OCTA.\n* Ability and willingness to provide written informed consent.\n* Women of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use a reliable form of contraception for the duration of the study.\n\nExclusion Criteria:\n\n* Presence of ocular inflammation or primary choroidal disorders.\n* Presence of polypoidal choroidal vasculopathy (PCV).\n* Any ocular condition that, in the opinion of the investigator, could affect intra- or subretinal fluid or significantly alter visual acuity during the study (e.g., diabetic macular edema, retinal vein occlusion, uveitis, neovascular glaucoma).\n* Clinically significant cataract likely to reduce visual acuity by more than three ETDRS lines (i.e., worse than approximately 20\u002F40 if the eye were otherwise normal).\n* Any intraocular surgery within 3 months prior to enrollment.\n* Prior treatment in the study eye with:\n\n  * Intravitreal corticosteroids (any time),\n  * Anti-VEGF therapy within 6 months, or\n  * Photodynamic therapy (any time).\n* History of retinal detachment or surgery for retinal detachment, prior vitrectomy, or presence of a full-thickness macular hole.\n* Evidence of vitreomacular traction that may preclude resolution of macular edema.\n* Extensive intra- or subretinal hemorrhage exceeding 4 disc areas.\n* Aphakia in the study eye.\n* Pregnancy or breastfeeding.\n* Any medical, psychiatric, or systemic condition that, in the opinion of the investigator, would make study participation unsafe or interfere with study assessments.","ALL","21 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Dysregulation of the Angiopoietin-2 (Ang-2)\u002FTyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.\n\nThis study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.",[26],"Central Serous Chorioretinopathy (CSC)","NOT_YET_RECRUITING","2026-06-26",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":20},"2026-12",{"date":35,"type":20},"2029-08",{"name":37,"class":38},"Singapore National Eye Centre","OTHER_GOV",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100619630","prospective-geometric-analysis-of-ultra-widefield-octa-characteristics-in-central-serous-chorioretinopathy-patients-100619630","NCT07347119","Prospective Geometric Analysis of Ultra-Widefield OCTA Characteristics in Central Serous Chorioretinopathy Patients","Inclusion Criteria:\n\n* Adults aged 18 to 60 years, inclusive;\n* Clinical diagnosis of central serous chorioretinopathy (CSC);\n* Completion of fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) examinations;\n* Completion of ultra-widefield optical coherence tomography angiography (UWF-OCTA) imaging;\n* No prior history of pharmacological or surgical treatment for CSC;\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n-Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage);\n\n* Presence of systemic diseases that may affect study outcomes or participant safety;\n* Pregnant or lactating women;\n* History of psychiatric or mental disorders that may impair compliance;\n* Hemorrhagic diathesis or requirement for long-term anticoagulant therapy;\n* History of long-term systemic medication use that may affect choroidal or retinal circulation;\n* Presence of severe and\u002For uncontrolled comorbid medical conditions, including but not limited to:\n\nUncontrolled diabetes mellitus; Uncontrolled hypertension; Active uncontrolled infection; Chronic obstructive pulmonary disease (COPD) with dyspnea at rest;\n\n* History of intraocular surgery or intravitreal injection within the past 6 months;\n* High refractive error defined as:\n\nSpherical equivalent (SE) \\\u003C -6.0 diopters or \\> +3.0 diopters, or Axial length (AL) \\> 26.0 mm;\n\n-Any other condition that, in the opinion of the investigator, would make participation unsafe or interfere with protocol adherence.",true,"18 Years","60 Years",{"count":49,"type":20},120,"OBSERVATIONAL","By leveraging parameters including fractal dimension and topological index, we constructed a quantitative evaluation framework for ultra-widefield optical coherence tomography angiography (UWF-OCTA) images in patients with central serous chorioretinopathy (CSC), thus overcoming the limitations of conventional qualitative analysis.",[26],[54,55,56],"Central Serous Chorioretinopathy","Ultra-Widefield Optical Coherence Tomography Angiography","Geometry","2026-01-08",{"date":59,"type":31},"2026-01-16",{"date":61,"type":20},"2025-12-18",{"date":63,"type":20},"2027-06-30",{"name":65,"class":66},"Sun Yat-sen University","OTHER",1]